Michael Dawes | Profiles RNS

Michael A. Dawes, MD

Clinical Professor

Boston University Chobanian & Avedisian School of Medicine

Psychiatry

MD, University of North Carolina School of Medicine
BA, University of North Carolina at Chapel Hill

Websites

	Boston Medical Center Provider Profile
	Psychiatry Faculty
	LinkedIn

ORCID : 0000-0002-4227-0098

Michael Dawes, M.D. is Clinical Professor in Psychiatry at Boston University School of Medicine (BUSM). Dr. Dawes is Program Director, BMC-VA Addiction Psychiatry Fellowship. Dr. Dawes has been recipient of a Mentored Clinical Scientist Development Award from the National Institute on Drug Abuse, and has been PI and Site-PI on clinical and prospective studies funded by the National Institutes of Health. He has experience designing and implementing quality improvement and systems redesign projects in the Veterans Healthcare Administration and has served as a site-PI for a multi-site study. He is currently Co-PD on a Health Resources and Services Administration (HRSA) Addiction Medicine Fellowship grant. Dr. Dawes has mentored and supervised faculty as well as many residents, fellows, and other trainees with interests in Addiction Psychiatry, Addiction Medicine, and clinical research in populations with substance use disorders. He is interested in training fellows to do clinical research, including research and implementation science addressing access to treatment for individuals and populations with substance use disorders.

Program Director
Boston University Chobanian & Avedisian School of Medicine
Addiction Psychiatry Fellowship

NIH RePORTER Research

Title

Yr	Title	Project-Sub Proj	Pubs
2009	Impulsivity and Abstinence Outcomes in Cannabis-Using Adolescents	5R21DA022711-02	2
2008	Impulsivity and Abstinence Outcomes in Cannabis-Using Adolescents	1R21DA022711-01A1	2
2002	Health behavior module	5P50DA005605-13-5	291
2001	Health behavior module	5P50DA005605-12-5	291
2000	Health behavior module	3P50DA005605-11A1S1-5	291
2000	Health behavior module	2P50DA005605-11A1-5	291
1999	DRUG USE LIABILITY DURING PUBERTAL DEVELOPMENT	7K08DA000299-04	1
1999	DRUG USE LIABILITY DURING PUBERTAL DEVELOPMENT	5K08DA000299-03	1

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Sung ML, Black AC, Blevins D, Henry BF, Cates-Wessel K, Dawes MA, Drexler K, Hagle H, Molfenter T, Levin FR, Becker WC, Edelman EJ. Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers. J Addict Med. 2022 Sep-Oct 01; 16(5):505-513. PMID: 35020698; PMCID: PMC9271533; DOI: 10.1097/ADM.0000000000000948;

Hagedorn HJ, Wisdom JP, Gerould H, Pinsker E, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Harris AHS. Alcohol use disorder pharmacotherapy and treatment in primary care (ADaPT-PC) trial: Impact on identified barriers to implementation. Subst Abus. 2022; 43(1):1043-1050. PMID: 35467489

Blevins D, Henry BF, Sung M, Edelman EJ, Black AC, Dawes M, Molfenter T, Hagle H, Drexler K, Cates-Wessel K, Levin FR. Well-Being of Health Care Professionals Treating Opioid Use Disorder During the COVID-19 Pandemic: Results From a National Survey. Psychiatr Serv. 2022 Apr 01; 73(4):374-380. PMID: 34369804; PMCID: PMC8825878; DOI: 10.1176/appi.ps.202100080;

Baig MR, Ouyang S, Mata-Galán E, Dawes MA, Roache JD. A Comparison of Cognitive Processing Therapy and Seeking Safety for the Treatment of Posttraumatic Stress Disorder in Veterans. Psychiatr Q. 2021 06; 92(2):735-750. PMID: 32964375

Hagedorn HJ, Wisdom JP, Gerould H, Pinsker E, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Harris AHS. Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. Addict Sci Clin Pract. 2019 07 10; 14(1):24. PMID: 31291996; PMCID: PMC6617941; DOI: 10.1186/s13722-019-0151-7;

Harris AHS, Brown R, Dawes M, Dieperink E, Myrick DH, Gerould H, Wagner TH, Wisdom JP, Hagedorn HJ. Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration. J Subst Abuse Treat. 2017 11; 82:107-112. PMID: 29021108; DOI: 10.1016/j.jsat.2017.09.002;

Hagedorn HJ, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Wisdom JP, Harris AH. Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. Implement Sci. 2016 May 10; 11:64. PMID: 27164835; PMCID: PMC4862158; DOI: 10.1186/s13012-016-0431-5;

Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016 08; 111(8):1416-27. PMID: 26948856; PMCID: PMC4940267; DOI: 10.1111/add.13375;

Acheson A, Ray KL, Hines CS, Li K, Dawes MA, Mathias CW, Dougherty DM, Laird AR. Functional activation and effective connectivity differences in adolescent marijuana users performing a simulated gambling task. J Addict. 2015; 2015:783106. PMID: 25692068; PMCID: PMC4321681; DOI: 10.1155/2015/783106;

Dougherty DM, Hill-Kapturczak N, Ryan SR, Mathias CW, Dawes MA, Acheson A, Charles NE, Furr MA, Liguori A. Ethical considerations in adolescent drug research. Psychopharmacology (Berl). 2014 Apr; 231(8):1433-5. PMID: 24800274

Showing 10 of 41 results. Show More

James LM, Mathias CW, Bray BC, Cates SE, Farris SJ, Dawes MA, Hill-Kapturczak N, Dougherty DM. Acquisition of Rater Agreement for the Stressful Life Events Schedule. J Alcohol Drug Depend. 2013; 1(5). PMID: 34651055

Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles NE, Liguori A, Shannon EE, Acheson A. Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology (Berl). 2013 Mar; 226(2):307-19. PMID: 23138434; PMCID: PMC3581724; DOI: 10.1007/s00213-012-2908-5;

Ait-Daoud N, Seneviratne C, Smith JB, Roache JD, Dawes MA, Liu L, Wang XQ, Johnson BA. Preliminary Evidence for cue-induced Alcohol Craving Modulated by Serotonin Transporter Gene Polymorphism rs1042173. Front Psychiatry. 2012; 3:6. PMID: 22355291; PMCID: PMC3280410; DOI: 10.3389/fpsyt.2012.00006;

Mathias CW, Dougherty DM, James LM, Richard DM, Dawes MA, Acheson A, Hill-Kapturczak N. Intolerance to delayed reward in girls with multiple suicide attempts. Suicide Life Threat Behav. 2011 Jun; 41(3):277-86. PMID: 21463352; PMCID: PMC3110978; DOI: 10.1111/j.1943-278X.2011.00027.x;

Mathias CW, Blumenthal TD, Dawes MA, Liguori A, Richard DM, Bray B, Tong W, Dougherty DM. Failure to sustain prepulse inhibition in adolescent marijuana users. Drug Alcohol Depend. 2011 Jul 01; 116(1-3):110-6. PMID: 21196088; PMCID: PMC3091950; DOI: 10.1016/j.drugalcdep.2010.11.020;

Dawes MA, Roache JD, Javors MA, Bergeson SE, Richard DM, Mathias CW, Ait-Daoud N, Dougherty DM, Johnson BA. Drinking histories in alcohol-use-disordered youth: preliminary findings on relationships to platelet serotonin transporter expression with genotypes of the serotonin transporter. J Stud Alcohol Drugs. 2009 Nov; 70(6):899-907. PMID: 19895766; PMCID: PMC2776120; DOI: 10.15288/jsad.2009.70.899;

Dougherty DM, Mathias CW, Marsh-Richard DM, Prevette KN, Dawes MA, Hatzis ES, Palmes G, Nouvion SO. Impulsivity and clinical symptoms among adolescents with non-suicidal self-injury with or without attempted suicide. Psychiatry Res. 2009 Aug 30; 169(1):22-7. PMID: 19631392; PMCID: PMC3062197; DOI: 10.1016/j.psychres.2008.06.011;

Dougherty DM, Mathias CW, Marsh-Richard DM, Furr RM, Nouvion SO, Dawes MA. Distinctions in Behavioral Impulsivity: Implications for Substance Abuse Research. Addict Disord Their Treat. 2009 Jun 01; 8(2):61-73. PMID: 20535237; PMCID: PMC2882111; DOI: 10.1097/ADT.0b013e318172e488;

Ait-Daoud N, Roache JD, Dawes MA, Liu L, Wang XQ, Javors MA, Seneviratne C, Johnson BA. Can serotonin transporter genotype predict craving in alcoholism? Alcohol Clin Exp Res. 2009 Aug; 33(8):1329-35. PMID: 19426172; PMCID: PMC2747793; DOI: 10.1111/j.1530-0277.2009.00962.x;

Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM. L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications. Int J Tryptophan Res. 2009 Mar 23; 2:45-60. PMID: 20651948; PMCID: PMC2908021; DOI: 10.4137/ijtr.s2129;

Dawes MA, Mathias CW, Richard DM, Hill-Kapturczak N, Dougherty DM. Adolescent Suicidal Behavior and Substance Use: Developmental Mechanisms. Subst Abuse. 2008 Oct 31; 2:13-28. PMID: 20651946; PMCID: PMC2907920; DOI: 10.4137/sart.s1044;

Dawes MA, Richard DM, Mathias CW, Dougherty DM. Prospective study of cannabis withdrawal in cannabis-using adolescents. J Am Acad Child Adolesc Psychiatry. 2008 Sep; 47(9):1095-6; author reply 1096. PMID: 18714196; PMCID: PMC2631204; DOI: 10.1097/CHI.0b013e31817eed64;

Johnson BA, Javors MA, Roache JD, Seneviratne C, Bergeson SE, Ait-Daoud N, Dawes MA, Ma JZ. Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking? Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 01; 32(1):209-16. PMID: 17950969; PMCID: PMC2270792; DOI: 10.1016/j.pnpbp.2007.07.030;

Dougherty DM, Marsh DM, Mathias CW, Dawes MA, Bradley DM, Morgan CJ, Badawy AA. The effects of alcohol on laboratory-measured impulsivity after L: -Tryptophan depletion or loading. Psychopharmacology (Berl). 2007 Jul; 193(1):137-50. PMID: 17377773

Johnson BA, Wells LT, Roache JD, Wallace CL, Ait-Daoud N, Dawes MA, Liu L, Wang XQ, Javors MA. Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30; 31(2):455-61. PMID: 17184890; PMCID: PMC1847340; DOI: 10.1016/j.pnpbp.2006.11.011;

Dawes MA, Liguori A, Dougherty DM. Cannabis withdrawal among adolescent cannabis users in an outpatient research setting. Am J Addict. 2006 Nov-Dec; 15(6):485-6. PMID: 17182454

Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang XQ. Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30; 31(1):123-30. PMID: 16978753; PMCID: PMC1810424; DOI: 10.1016/j.pnpbp.2006.08.002;

Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang XQ. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol. 2007 Feb; 10(1):85-98. PMID: 16448579

Dawes MA, Johnson BA, Ma JZ, Ait-Daoud N, Thomas SE, Cornelius JR. Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav. 2005 Oct; 30(9):1630-7. PMID: 16084024

Johnson BA, Dawes MA, Roache JD, Wells LT, Ait-Daoud N, Mauldin JB, Wang Y, Lancaster JL, Fox PT. Acute intravenous low- and high-dose cocaine reduces quantitative global and regional cerebral blood flow in recently abstinent subjects with cocaine use disorder. J Cereb Blood Flow Metab. 2005 Jul; 25(7):928-36. PMID: 15758948

Johnson BA, Roache JD, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y. Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. Int J Neuropsychopharmacol. 2005 Jun; 8(2):203-13. PMID: 15850499

Johnson BA, Roache JD, Ait-Daoud N, Wallace CL, Wells LT, Wang Y, Dawes MA. Effects of isradipine on cocaine-induced changes in cognitive performance in recently abstinent cocaine-dependent individuals. Int J Neuropsychopharmacol. 2005 Dec; 8(4):549-56. PMID: 15916717

Dawes MA, Johnson BA, Ait-Daoud N, Ma JZ, Cornelius JR. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav. 2005 Jul; 30(6):1077-85. PMID: 15925118

Dawes MA, Johnson BA. Pharmacotherapeutic trials in adolescent alcohol use disorders: opportunities and challenges. Alcohol Alcohol. 2004 May-Jun; 39(3):166-77. PMID: 15082452

Dawes MA, Antelman SM, Vanyukov MM, Giancola P, Tarter RE, Susman EJ, Mezzich A, Clark DB. Developmental sources of variation in liability to adolescent substance use disorders. Drug Alcohol Depend. 2000 Dec 22; 61(1):3-14. PMID: 11064179

Ammerman RT, Kolko DJ, Kirisci L, Blackson TC, Dawes MA. Child abuse potential in parents with histories of substance use disorder. Child Abuse Negl. 1999 Dec; 23(12):1225-38. PMID: 10626607

Dawes MA, Dorn LD, Moss HB, Yao JK, Kirisci L, Ammerman RT, Tarter RE. Hormonal and behavioral homeostasis in boys at risk for substance abuse. Drug Alcohol Depend. 1999 Jun 01; 55(1-2):165-76. PMID: 10402161

Dawes M, Clark D, Moss H, Kirisci L, Tarter R. Family and peer correlates of behavioral self-regulation in boys at risk for substance abuse. Am J Drug Alcohol Abuse. 1999 May; 25(2):219-37. PMID: 10395157; DOI: 10.1081/ada-100101857;

Tarter R, Vanyukov M, Giancola P, Dawes M, Blackson T, Mezzich A, Clark DB. Etiology of early age onset substance use disorder: a maturational perspective. Dev Psychopathol. 1999; 11(4):657-83. PMID: 10624720

Dawes MA, Tarter RE, Kirisci L. Behavioral self-regulation: correlates and 2 year follow-ups for boys at risk for substance abuse. Drug Alcohol Depend. 1997 May 02; 45(3):165-76. PMID: 9179518

Dawes MA, Frank S, Rost K. Clinician assessment of psychiatric comorbidity and alcoholism severity in adult alcoholic inpatients. Am J Drug Alcohol Abuse. 1993; 19(3):377-86. PMID: 8213701

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 41 publications over 22 distinct years, with a maximum of 5 publications in 2009